Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia

Limei Wu; Srinivas Chatla; Qiqi Lin; Fabliha Ahmed Chowdhury; Werner Geldenhuys; Wei Du

doi:10.1038/s41467-021-27300-w

Nature Communications (Nov 2021)

Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia

Limei Wu,
Srinivas Chatla,
Qiqi Lin,
Fabliha Ahmed Chowdhury,
Werner Geldenhuys,
Wei Du

Affiliations

Limei Wu: Division of Hematology and Oncology, University of Pittsburgh School of Medicine
Srinivas Chatla: Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine at Temple University
Qiqi Lin: Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University
Fabliha Ahmed Chowdhury: Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University
Werner Geldenhuys: Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University
Wei Du: Division of Hematology and Oncology, University of Pittsburgh School of Medicine

DOI: https://doi.org/10.1038/s41467-021-27300-w
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Chemoresistance and relapse are main limitations in the treatment of acute lymphoblastic leukemia (ALL). Here, the authors identify Quinacrine (QC) as a sensitizer for Cytarabine (AraC) and establish a QC-CASIN regimen to improve leukemia eradication in ALL.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal